CD-16 NK-92 cells

DB17465InvestigationalCell transplant therapies

CD-16 NK-92 cells: Overview.

Mechanism: Pharmacologically active on Interleukin-2, Low affinity immunoglobulin gamma Fc region receptor III-A, and Immunoglobulin heavy constant gamma 1
Curator reviewed
Also known as: haNK · High-affinity CD16-expressing natural killer cell therapy · NK-92 [CD16.158V, ER IL-2]
Code names: CD-16 NK-92 cells

Resolves to

Compound

Targets

What you can answer from here — as of July 08, 2026

4Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

23Clinical trialsPhase, status and sponsor resolved per trial

7+ReferencesStructured and connected to the statements they support

Which drugs share a target with CD-16 NK-92 cells, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.